Vertex Pharmaceuticals

Refresh delta (since 2026-06-17)

1. Vertex agreed to buy Crinetics for about $10.0B in cash, a subsequent event the dossier does not have. Merger agreement dated 2026-07-06: $85.00 per Crinetics share, about $10.0B total equity value, closing expected in Q3 2026 subject to customary conditions. It brings PALSONIFY (paltusotine, for acromegaly, approved by the FDA and EMA) and atumelnant (Phase 3, congenital adrenal hyperplasia). Funding is cash on hand plus a term loan; the acquisition is not conditioned on financing [sec.gov: 10-QForm 10-QThe quarterly version of the annual report. Lighter, and not audited. filed 2026-08-04, https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm].

2. New debt facilities, none drawn at 2026-08-04. On 2026-07-30, Vertex signed a $4.5B senior unsecured delayed-draw term loan A: $1.0B due 364 days after funding, $1.0B at two years and $2.5B at three years. A 364-day bridge commitment dated 2026-07-06 was terminated the same day. A new $500.0M revolver matures 2031-07-30, and replaced a 2022 $500.0M revolver. Both new facilities carry a 3.50x maximum leverage ratio, which can rise to 4.00x for four quarters after a material acquisition.

3. Q2 2026 revenue was $3,333.9M, up 12% YoY; first-half revenue was $6,320.8M, up 10%. All of it was product revenue. Q2 GAAP operating income was $1,246.9M; GAAP net income $1,099.8M; GAAP diluted EPS $4.31 on 255.2M diluted shares (vs $3.99). First-half GAAP diluted EPS was $8.33. Non-GAAP EPS is not in the 10-Q and is left out.

4. Product mix, Q2 2026 vs Q2 2025:

• Trikafta/Kaftrio $2,497.2M (−2%)
• Alyftrek $573.6M (+266%, from $156.8M)
• Other CF (Kalydeco, Orkambi, Symdeko/Symkevi, combined) $137.1M (−29%)
• Casgevy $76.4M (+151%; +78% on Q1's $42.9M )
• Journavx $49.6M (+313%; +71% on Q1's $29.0M )

CF share of Q2 product revenue. Casgevy plus Journavx revenue was in Q2 and in the first half.

1. Geography, Q2 2026. US $2,056.4M (+11%); ex-US $1,277.5M (+14%, with favourable FX and Alyftrek uptake).

2. SG&A grew faster than revenue. Q2 SG&A was $582.2M, up 37% YoY (31% for the half); R&D was $993.8M, up 2%. Acquired IPR&D was $21.4M. Operating margin.

3. Cash and capital return. Cash, equivalents and marketable securities were $13,641.5M at 2026-06-30 vs $12,320.4M at 2025-12-31. First-half operating cash flow was $2,553.5M and capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. $245.6M. Vertex repurchased 1.8M shares for $799.5M in the half, leaving $2.6B on the 2025 authorization. Goodwill was $1,088.0M and other intangibles $412.8M.

4. Povetacicept has a PDUFA date. The FDA accepted the BLA for accelerated approval of povetacicept in adults with IgAN, with a target action date of 2026-11-30. The company says it is preparing for a potential launch. The Phase 2B portion of the Phase 2/3 OLYMPUS trial in primary membranous nephropathy is complete, and the Phase 3 portion is underway.

5. Other pipeline and label items, as the 10-Q words them:

• Inaxaplin (AMPLITUDE): full enrollment expected in 2H 2026 and interim-analysis data "in early 2027", once the interim cohort has 48 weeks of treatment. The dossier said "late 2026/early 2027".
• Suzetrigine in diabetic peripheral neuropathy: enrollment in both Phase 3 trials expected to complete by end-2026. Health Canada accepted the acute-pain submission.
• Zimislecel: "enrolling and dosing" in the Phase 1/2/3 trial, with updated timelines for zimislecel and the new VX-017 program to be given in 2026. The 10-Q does not restate a 2026 filing target and does not use the words "manufacturing analysis" or "postponed".
• Casgevy: FDA approval for children aged two and over with SCD or TDT, and reimbursement secured in Germany in May.
• Alyftrek: reimbursed in 25 countries; pediatric (ages 2–5) submissions begun.

1. Journavx volume. About 535,000 prescriptions were filled in Q2 and 900,000 in the first half. Three of the four major Medicare Part D PBMs now reimburse it, and about 260 million people have reimbursed access. The dossier cited "550k+" prescriptions for 2025.

2. Legal disclosure. Part II Item 1 says that apart from the matters in Note L, Vertex is "not currently subject to any material legal proceedings". Note L covers the credit facilities; it does not mention a securities class action or the HHS/OIG fertility-program case, both of which the dossier's Lens 10 describes. Neither matter's status is therefore updated by this filing.

Where the new facts touch the dossier's own lines (stated as fact; the lines stay as written). The verdict reads "priced for a successful four-engine diversification… only one-third proven". The 10-Q shows Casgevy and Journavx at $126.0M in Q2 and a PDUFA date for the first renal product. The seed lists a "zimislecel T1D regulatory filing… 2026" catalyst; the 10-Q says updated timelines will come in 2026. The seed lists the inaxaplin interim as "late 2026 / early 2027"; the 10-Q says early 2027. The seed's key risks name "~86%" CF concentration; Q2 CF product revenue was 96.2% of product revenue (item 4). The seed's cash-fortress framing is unchanged in the filing, but Vertex has now arranged $4.5B of term debt for a $10.0B acquisition that the seed does not mention. No MarketCall is referenced in the dossier.

What held

• CF remains the engine: Q2 CF revenue was $3,207.9M, and total revenue grew 12% (items 3, 4).
• Alyftrek is displacing Trikafta, as the dossier described, with Trikafta down 2% and Alyftrek up 266% (item 4).
• Cash generation is strong ($2,553.5M operating cash flow in the half) and buybacks continue (item 7).
• Casgevy and Journavx are growing from small bases, and renal is moving toward a first approval decision (items 4, 8).